RBC Capital downgraded Jasper Therapeutics (JSPR) to Sector Perform from Outperform with a price target of $5, down from $46.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- Hold Rating for Jasper Therapeutics Amid Uncertainties in Briquilimab’s Clinical Trials and Competitive Challenges
- Cantor cuts Jasper Therapeutics to Neutral after briquilimab update
- Jasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Buy Rating Maintained for Jasper Therapeutics Amid Manufacturing Setback and Promising Drug Profile